Comparative Pharmacokinetics of Two Alendronic Acid Formulations in Healthy Volunteers: A Randomized, Open-Label, Single-Dose, Crossover Study

The primary objective of this study is to evaluate the **pharmacokinetics** of two formulations of alendronic acid in healthy volunteers under fasted conditions. This is a pilot study designed to compare the absorption, distribution, metabolism, and excretion of the drug, which is crucial for understanding its efficacy and safety profile. The study is conducted in a randomised, open-label, single-dose, two-period crossover design, which allows for a direct comparison of the two formulations in the same subjects, thereby minimizing inter-subject variability. The clinical relevance of this study lies in its potential to inform dosing recommendations and optimize therapeutic outcomes for patients who may eventually receive these formulations. No secondary objectives are specified for this study.

The clinical trial involves a study population comprising both **male** and **female** participants, with an age range categorized as adults. The trial is a pharmacokinetic study conducted in **healthy subjects**, indicating that participants are generally in good health. The sponsor has not provided the total number of participants involved in the study. The trial population was selected to include a vulnerable population, although specific lifestyle considerations such as diet, physical activity, or habits have not been detailed. The study does not focus on a specific medical condition, as it is not applicable in this context. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed as a **randomized**, open-label, single-dose, two-period crossover study to evaluate the comparative pharmacokinetics of two formulations of alendronic acid in healthy volunteers under fasted conditions. The study is categorized as a Phase 3 trial and is not applicable to any specific medical condition, as it involves healthy subjects. The trial is expected to commence recruitment on March 4, 2025, and conclude by March 19, 2025. The overall duration of the trial is brief, given the nature of the pharmacokinetic study.

Participants will undergo a sequence of study visits, beginning with an inclusion visit, which serves as the screening phase to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive one of the two alendronic acid formulations. The study involves two treatment periods, with each participant receiving both formulations in a crossover manner. The purpose of these visits is to collect pharmacokinetic data and ensure participant safety. Follow-up visits will be scheduled to monitor any adverse events and gather additional data as required. The end-of-study visit will mark the completion of the trial, where final assessments will be conducted, and participants will be debriefed.

The expected length of participant involvement is limited to the duration of the study, which spans approximately two weeks. Conditions that may lead to early termination from the study include non-compliance with study procedures, withdrawal of consent, or the occurrence of any adverse events that compromise participant safety. The study is structured to ensure rigorous data collection while maintaining the safety and well-being of all participants throughout the trial period.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 4, 2025, with an estimated completion date of March 19, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The trial's design and execution will be aligned with regulatory requirements to ensure the reliability and validity of the efficacy outcomes.